Becton, Dickinson and Company (NYSE:BDX) Issues Earnings Results

Posted by Francis Steltz on Nov 7th, 2026

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) announced its earnings results on Thursday. The medical instruments supplier reported $4.15 EPS for the quarter, beating analysts’ consensus estimates of $4.07 by $0.08, FiscalAI reports. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%. The company had revenue of $5.27 billion during the quarter, compared to analysts’ expectations of $5.11 billion. During the same period last year, the business posted $3.96 EPS. Becton, Dickinson and Company’s revenue for the quarter was up 5.4% on a year-over-year basis.

Here are the key takeaways from Becton, Dickinson and Company’s conference call:

BD reported Q4 revenue of $5.3 billion, up 5.6%, and adjusted EPS of $4.15, up 27.3%. For fiscal 2026, revenue increased 3.9% to $19.5 billion and adjusted EPS rose 6.7% to $12.70.
Executives cited broad momentum in growth platforms, including Advanced Patient Monitoring, PureWick, biologic drug delivery, advanced tissue regeneration, and Rowa pharmacy automation. They also highlighted share gains in Alaris and strong adoption of the Incada AI platform, while noting these results reflect targeted commercial and capacity investments.
Fiscal 2027 guidance calls for low-single-digit revenue growth and adjusted EPS of $13.10–$13.30, with operating margins roughly flat. Excluding an estimated 200-basis-point Alaris comparison headwind, revenue growth is expected to be mid-single-digit at the midpoint; Q1 growth is expected at the low end of the annual range.
Full-year free cash flow rose 42% to $2.9 billion, and conversion improved to approximately 74%, including separation costs; BD expects another meaningful step-up in fiscal 2027. The company returned $3.6 billion to shareholders and said its capital allocation priorities include buybacks, debt reduction, and focused tuck-in acquisitions.
BD agreed to invest $19 billion in the U.S. over several years, including $3 billion for manufacturing expansion; management said this is a reprioritization of planned investment, not incremental spending. Potential relief from future Section 232 tariffs is not included in guidance and depends on final rules and the company meeting agreed milestones.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock traded down $1.28 during trading hours on Friday, hitting $212.27. 2,172,550 shares of the company traded hands, compared to its average volume of 1,599,485. Becton, Dickinson and Company has a 1-year low of $137.35 and a 1-year high of $214.88. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. The firm has a market cap of $58.49 billion, a P/E ratio of 51.27, a P/E/G ratio of 13.39 and a beta of 0.22. The firm’s 50-day simple moving average is $188.17 and its two-hundred day simple moving average is $170.28.

Becton, Dickinson and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 31st. Investors of record on Thursday, December 10th will be given a $1.06 dividend. The ex-dividend date is Thursday, December 10th. This represents a $4.24 dividend on an annualized basis and a yield of 2.0%. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.05. Becton, Dickinson and Company’s payout ratio is currently 126.51%.

Becton, Dickinson and Company declared that its board has approved a stock buyback plan on Thursday, November 5th that authorizes the company to buy back 10,000,000 outstanding shares. This buyback authorization authorizes the medical instruments supplier to reacquire up to 3.6% of its stock through open market purchases. Share buyback plans are often a sign that the company’s board of directors believes its stock is undervalued.

Insider Transactions at Becton, Dickinson and Company

In related news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $185.00, for a total transaction of $768,120.00. Following the completion of the sale, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at $20,380,155. This represents a 3.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Feld sold 165 shares of the stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total value of $31,100.85. Following the sale, the executive vice president owned 19,720 shares of the company’s stock, valued at $3,717,022.80. This trade represents a 0.83% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 6,907 shares of company stock valued at $1,269,128. Corporate insiders own 0.40% of the company’s stock.

Key Becton, Dickinson and Company News

Here are the key news stories impacting Becton, Dickinson and Company this week:

Positive Sentiment: BD reported Q4 adjusted earnings of $4.15 per share and revenue of $5.27 billion, topping analyst expectations; revenue rose 5.4% year over year. BD fiscal 2026 results
Positive Sentiment: The board raised the quarterly dividend 1% to $1.06 per share and authorized repurchases of up to 10 million shares, or about 3.6% of shares outstanding. Dividend increase and share repurchase authorization
Positive Sentiment: Citigroup raised its price target to $241 and assigned a “buy” rating; Evercore ISI also lifted its target, to $230 from $210. Citigroup analyst rating Evercore ISI price target
Neutral Sentiment: RBC raised its target to $225 but kept a “sector perform” rating, while Piper Sandler raised its target to $200 and maintained “neutral”—below the stock’s recent trading level. RBC analyst rating Piper Sandler price target
Negative Sentiment: The main concern is the fiscal 2027 outlook: coverage reports say revenue-growth guidance came in just below expectations, tempering the impact of the Q4 beat and prompting investor concern. Fiscal 2027 guidance coverage

Wall Street Analyst Weigh In

BDX has been the topic of a number of recent research reports. Piper Sandler upped their price objective on Becton, Dickinson and Company from $175.00 to $200.00 and gave the stock a “neutral” rating in a research report on Friday. Barclays began coverage on Becton, Dickinson and Company in a report on Wednesday, October 7th. They issued an “underweight” rating and a $165.00 target price for the company. Royal Bank Of Canada upped their price objective on Becton, Dickinson and Company from $190.00 to $225.00 and gave the company a “sector perform” rating in a research note on Friday. Jefferies Financial Group reaffirmed a “buy” rating and issued a $242.00 price objective on shares of Becton, Dickinson and Company in a report on Thursday. Finally, Wolfe Research assumed coverage on Becton, Dickinson and Company in a research note on Tuesday, October 20th. They set an “outperform” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $193.67.

Get Our Latest Report on BDX

About Becton, Dickinson and Company

(Get Free Report)

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops and manufactures products used in healthcare, clinical laboratories and life sciences research. Founded in 1897, the company has a long history of producing medical devices and supplies.

BD’s products include syringes, needles, infusion systems and medication-management technologies, as well as equipment and supplies for collecting and processing clinical specimens. The company also provides diagnostic systems, laboratory instruments and tools used in areas such as cell analysis and biomedical research.

Its offerings serve hospitals, clinics, laboratories, researchers and pharmaceutical companies.